Leukemia & Lymphoma
Volume 65, 2024 - Issue 6
Open access
1,278
Views
0
CrossRef citations to date
0
Altmetric
Original Articles
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study
Aurore Perrota Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
https://orcid.org/0000-0003-0131-8689View further author information
Sosana Delimpasib General Hospital Evangelismos, Athens, Greece
https://orcid.org/0000-0001-7523-7510View further author information
Emmanouil Spanoudakisc University General Hospital of Evros-Alexandroupolis District, Alexandroupolis, Greece
https://orcid.org/0000-0003-4985-5862View further author information
Ulf Frølundd Department of Haematology, Zealand University Hospital, Roskilde, DenmarkView further author information
, Angelo Belottie Hematology Division, ASST Spedali Civili Brescia, Brescia, ItalyView further author information
, Albert Oriolf Hematology Department, Insitut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
https://orcid.org/0000-0001-6804-2221View further author information
Philippe Moreaug Hematology Department, University Hospital, Nantes, France
https://orcid.org/0000-0003-1780-8746View further author information
Ian McFaddenh Amgen Inc., Thousand Oaks, CA, USA
https://orcid.org/0009-0004-7488-8804View further author information
Qing Xiah Amgen Inc., Thousand Oaks, CA, USA
https://orcid.org/0009-0007-4120-2740View further author information
Mukta Arorah Amgen Inc., Thousand Oaks, CA, USA
https://orcid.org/0000-0001-9362-0556View further author information
Meletios Athanasios Dimopoulosi Section of Hematology and Medical Oncology, Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, GreeceCorrespondence[email protected]
https://orcid.org/0000-0001-8990-3254View further author information
Pages 833-842
|
Received 18 Nov 2024, Accepted 17 Feb 2024, Published online: 18 Mar 2024
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.